Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

作者： Marcello Tiseo , Luis Paz-Ares , Harry Groen , Maximilian Hochmair , Scott Gettinger